Co-Author
This page shows the publications co-authored by Noopur Raje and Steven Treon.
Connection Strength
1.002
-
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2018 09 20; 36(27):2755-2761.
Score: 0.207
-
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol. 2004 May; 125(3):343-52.
Score: 0.077
-
Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood. 2000 Nov 01; 96(9):3147-53.
Score: 0.061
-
Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin Oncol. 2000 Oct; 27(5):598-613.
Score: 0.060
-
Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis. Amyloid. 2000 Jun; 7(2):126-32.
Score: 0.059
-
Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. Blood. 1999 Mar 01; 93(5):1487-95.
Score: 0.054
-
Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood. 1999 Feb 15; 93(4):1287-98.
Score: 0.054
-
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 02; 15(2):230-269.
Score: 0.047
-
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. J Natl Compr Canc Netw. 2016 04; 14(4):389-400.
Score: 0.044
-
Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2015 Nov; 13(11):1398-435.
Score: 0.043
-
Multiple myeloma, version 1.2013. J Natl Compr Canc Netw. 2013 Jan 01; 11(1):11-7.
Score: 0.035
-
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Canc Netw. 2012 Oct 01; 10(10):1211-9.
Score: 0.035
-
Multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1146-83.
Score: 0.032
-
Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4.
Score: 0.029
-
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005 Jan; 128(2):192-203.
Score: 0.020
-
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001 Jul 01; 98(1):210-6.
Score: 0.016
-
Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage. J Immunol. 2000 Dec 01; 165(11):6347-55.
Score: 0.015
-
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000 Nov 01; 96(9):2943-50.
Score: 0.015
-
SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem. 2000 Sep 08; 275(36):27845-50.
Score: 0.015
-
Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6. Clin Cancer Res. 2000 Mar; 6(3):1180-9.
Score: 0.014
-
Isolation and characterization of human multiple myeloma cell enriched populations. J Immunol Methods. 2000 Feb 21; 235(1-2):11-9.
Score: 0.014
-
CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Blood. 2000 Feb 01; 95(3):1039-46.
Score: 0.014
-
RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene. 1999 Nov 18; 18(48):6733-40.
Score: 0.014
-
Functional interaction between retinoblastoma protein and stress-activated protein kinase in multiple myeloma cells. Cancer Res. 1999 Mar 15; 59(6):1192-5.
Score: 0.014
-
Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells. Blood. 1999 Mar 01; 93(5):1482-6.
Score: 0.013
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.